Welcome to our dedicated page for Traws Pharma SEC filings (Ticker: TRAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Traws Pharma, Inc. (NASDAQ: TRAW) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information on Traws’ clinical-stage antiviral programs, financial position, governance and executive compensation, and they complement the company’s press releases.
Through periodic reports such as the Form 10-K and proxy statements, Traws describes its business focus on developing investigational oral small molecule antivirals for respiratory viral diseases, including COVID-19, Long COVID, bird flu and seasonal influenza. The definitive proxy statement (DEF 14A) outlines board structure, incentive compensation plans and matters submitted to stockholders, while also providing context on corporate governance and director elections.
Current reports on Form 8-K, several of which are referenced in the provided data, document material events such as interim clinical data announcements for ratutrelvir, approval to proceed with Phase 2 COVID-19 studies, dosing of the first Phase 2 subjects, quarterly earnings releases, option and restricted stock unit grants to executives, and the appointment of new board members and officers. These filings also confirm that Traws’ common stock is listed on The Nasdaq Stock Market LLC under the symbol TRAW.
Investors and analysts can use this page to review how Traws reports on its clinical progress with ratutrelvir and tivoxavir marboxil, its legacy oncology programs rigosertib and narazaciclib, and its financial results and capital structure. Forms related to executive and director compensation, incentive plans and governance changes provide additional insight into how the company aligns management incentives with its development priorities.
Stock Titan enhances access to these filings by organizing them chronologically and by form type, and by offering AI-powered summaries that explain the key points of lengthy documents such as annual reports, quarterly updates and 8-Ks. This allows users to quickly understand the significance of new filings, track trends in Traws’ disclosures and identify items such as clinical milestones, financing arrangements or changes in leadership that may be important for evaluating TRAW stock.
Traws Pharma, Inc. disclosed that individual investor Jorey Chernett has filed a Schedule 13G reporting a sizable ownership position in the company’s common stock. Chernett reports beneficial ownership of 543,268 shares of common stock, representing 6.8% of the class, based on the issuer’s outstanding shares. The filing states that Chernett has sole power to vote and dispose of all 543,268 shares, with no shared voting or dispositive authority.
The Schedule 13G is a filing type used for investors who characterize their holdings as passive. Consistent with that, Chernett certifies that the securities were not acquired and are not held for the purpose or effect of changing or influencing control of Traws Pharma, and are not part of any group or control-related arrangement.
Traws Pharma, Inc. filed a Form 8-K to highlight a new regulatory and clinical update in its COVID-19 pipeline. The company issued a press release announcing that it has filed a U.S. Investigational New Drug Application with the Food and Drug Administration for tivoxavir marboxil, a potential treatment candidate. The same press release also provides updated results from an ongoing study of ratutrelvir, described as a ritonavir-free treatment being evaluated in both PAXLOVID®-eligible and ineligible patients with mild-to-moderate COVID-19. The press release is attached as an exhibit to the filing, and the company includes standard cautionary language about forward-looking statements and the risks and uncertainties around future results.
Traws Pharma, Inc. filed a current report describing that it issued a press release announcing positive interim data from its Phase 2 study of ratutrelvir, a ritonavir-free treatment, in newly diagnosed COVID subjects. The filing emphasizes that these results are preliminary and accompanied by customary forward-looking statements language, highlighting that actual outcomes may differ due to various risks and uncertainties. The press release with additional details is included as an exhibit.
Traws Pharma, Inc. reported a new equity award to one of its directors. On 12/12/2025, the director acquired 4,058 restricted stock units of common stock at a stated price of $0 per share and was granted 16,234 stock options with a $2.33 exercise price. The restricted stock units will vest 100% on the first anniversary of the grant date, with each unit converting into one share of common stock. The stock options also vest 100% on the first anniversary of the grant date and are exercisable into 16,234 shares of common stock from 12/12/2026 until their expiration on 12/12/2035.
Traws Pharma director Trafford Clarke reported receiving new equity compensation. On 12/12/2025 he was granted 6,157 restricted stock units at $0 that will vest 100% on the first anniversary of the grant date, with each unit converting into one share of common stock.
He also received a stock option covering 24,629 shares of Traws Pharma common stock at an exercise price of $2.33 per share, which becomes fully exercisable on 12/12/2026 and expires on 12/12/2035. After these grants, he holds 6,157 restricted stock units and 24,629 stock options, all reported as directly owned.
Traws Pharma, Inc. director Werner Cautreels reported equity awards dated 12/12/2025. He received 4,874 restricted stock units at a price of $0, increasing his directly held common stock to 109,222 shares.
He was also granted stock options for 19,496 shares of common stock at an exercise price of $2.33, expiring 12/12/2035. The restricted stock units and the options each vest 100% on the first anniversary of the grant date.
Traws Pharma, Inc. director Mary Teresa Shoemaker reported equity awards dated 12/12/2025. She received 6,157 restricted stock units of common stock at a reported price of $0, leaving her with 6,292 common shares beneficially owned directly after the transaction. The filing states these restricted stock units will vest 100% on the first anniversary of the grant date, with each unit converting into one share of common stock. She was also granted a stock option for 24,629 shares of common stock at an exercise price of $2.33 per share, which becomes exercisable on 12/12/2026 and expires on 12/12/2035, and was reported as acquired at a price of $0.
Traws Pharma, Inc. reported an insider equity award for director Jack E. Stover. On 12/12/2025, he received an award of 6,157 restricted stock units. According to the disclosure, these restricted stock units vest 100% on the first anniversary of the grant date, and each unit converts into one share of common stock.
On the same date, Stover was also granted a stock option for 24,629 shares of common stock at an exercise price of $2.33 per share. The option becomes exercisable on 12/12/2026 and expires on 12/12/2035. After these transactions, he beneficially owned 6,165 shares of common stock and 24,629 stock options, all held directly.
Traws Pharma, Inc. reported an insider equity award for its Chief Executive Officer and director, Iain Dukes. On 12/12/2025, he acquired 36,943 shares of common stock at a price of $0 through an award of restricted stock units, bringing his directly held common stock holdings to 171,130 shares. These restricted stock units are scheduled to vest 100% on the first anniversary of the grant date and each unit will convert into one share of common stock.
On the same date, Dukes received a stock option covering 147,771 shares of common stock with an exercise price of $2.33 per share, granted at a price of $0. These options vest 100% on 12/12/2026 and expire on 12/12/2035, and he beneficially owns 147,771 stock options following this grant.
Traws Pharma, Inc. reported that its Chief Science Officer for Virology received new equity awards on December 12, 2025. The filing shows an acquisition of 18,471 shares of common stock, described as restricted stock units that will vest 100% on the first anniversary of the grant date, with each unit converting into one share of common stock. Following this grant, the officer beneficially owns 115,971 shares of common stock.
The officer was also granted a stock option for 73,886 shares of common stock at an exercise price of $2.33 per share. These options vest 100% on the first anniversary of the grant date, becoming exercisable on December 12, 2026, and expire on December 12, 2035. Both the common stock and the options are held directly.
FAQ
What is the current stock price of Traws Pharma (TRAW)?
What is the market cap of Traws Pharma (TRAW)?
